

AD-HOC ANNOUNCEMENT

(pursuant to section 15 WpHG)

MeVis Medical Solutions AG
Universitaetsallee 29
28359 Bremen
Germany

Phone: +49 421 224 95 0
Fax: +49 421 22495 11
E-mail: ir@mevis.de

MeVis Medical Solutions AG announces preliminary figures for 2011

EBITDA and EBIT above prior year – but EBIT burdened by mainly non-cash, one-time charges

Bremen, February 14, 2012 – MeVis Medical Solutions AG [ISIN: DE000A0LBF4], a leading software provider for the medical imaging market, has achieved based on preliminary figures, a Group turnover for fiscal year 2011 of approx. EUR 13.7 million (previous year: EUR 14.3 million) and an EBITDA of around EUR 4.1 million (previous year: EUR 3.5 million). The Group EBIT of approx. EUR -1.7 million (previous year: EUR -5.4 million) was burdened by mainly non-cash, one-time charges. Compared to the previous year, Group EBIT before one-time charges was improved by approx. EUR 0.2 million to approx. EUR 0.9 million.

Group EBIT of EUR -1.7 million impacted by one-time charges in the amount of EUR 2.6 million

The one-time charges impacting the EBIT consist of a non-cash impairment charge on intangible assets in the amount of approx. EUR 2.3 million for capitalized development expenses of Visia Software Applications since 2008. In addition, a provision has been made for the contractual obligations to the CEO, Dr. Carl Evertsz, who will leave the company on February 29, 2012.

Impairment of EUR 2.3 million for Visia Software Applications

The financial result was impacted by a partial write-off of the 41% stake in the Dutch company Medis in the amount of EUR 0.9 million. This non-cash write-off was due to an adjusted assessment of the future development.

Partial write-off in Medis stake by EUR 0.9 million

On December 31, 2011 the Group's liquidity amounted to EUR 7.6 million. Liquidity therefore decreased by just EUR 0.6 million, despite a EUR 3.0 million payment in 2011 for the acquisition of the 49% stake in the MBS KG in 2008.

The complete consolidated financial statement, the Group management report and the forecast for the current fiscal year will be released on April 24, 2012.

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.